key: cord-0782121-ep1ahytx
authors: Spector-Bagdady, Kayte
title: Governing secondary research use of health data and specimens: the inequitable distribution of regulatory burden between federally funded and industry research
date: 2021-05-20
journal: J Law Biosci
DOI: 10.1093/jlb/lsab008
sha: 3c1e914bbcf3d75e806e55fff2c04d79e161176b
doc_id: 782121
cord_uid: ep1ahytx

Some of the most promising recent advances in health research offer opportunities to improve diagnosis and therapy for millions of patients. They also require access to massive collections of health data and specimens. This need has generated an aggressive and lucrative push toward amassing troves of human data and biospecimens within academia and private industry. But the differences between the strict regulations that govern federally funded researchers in academic medical centers (AMCs) versus those that apply to the collection of health data and specimens by industry can entrench disparities. This article will discuss the value of secondary research with data and specimens and analyze why AMCs have been put at a disadvantage as compared to industry in amassing the large datasets that enable this work. It will explore the limitations of this current governance structure and propose that, moving forward, AMCs should set their own standards for commercialization of the data and specimens they generate in-house, the ability of their researchers to use industry data for their own work, and baseline informed consent standards for their own patients in order to ensure future data accessibility.

Some of the most promising recent advances in health research-including 'precision medicine' and other genetic, machine learning, and big-data protocols-o er opportunities to improve diagnosis and therapy for millions of patients. 1,2 They also require access to massive collections of health data and specimens to analyze the correlations between genetic variants, behaviors, environment, and health outcomes. 3 This need has generated an aggressive and lucrative push toward amassing troves of human biospecimens, health, and health-proxy data. 4 But there are profound differences between the strict federal human subjects research regulations that govern federally funded researchers versus the rules that apply to the collection of health data and specimens by industry. This di erence can entrench disparities in the value and breadth of data available as between the two. But why would the US government make it harder for federally funded researchers to accomplish their work than industry-funded ones?

In 2019 the US Department of Health and Human Services substantively revised the 'Common Rule' portion of the Human Subjects Research Regulations (which generally regulate federally-funded researchers) for the rst time since its original conceptualization in the 1980s. 5, 6 The revisions attempted to signi cantly update governance over the emerging area of 'secondary research' with data or biospecimens, ie research in addition to the clinical care or primary research protocol for which the biospecimen or data were originally procured.

In the wake of the immensely popular book The Immortal Life of Henrietta Lacks, 7 and related empirical studies, 8 data, which is easier to collect when people have a compelling basic interest in sharing it (ie at a hospital or clinic), as well as when insurance is reimbursing to annotate health information in detail. In addition, industry needs academic collaborators to conduct research, publish articles, and treat the patients and write the prescriptions that make the private data valuable in the rst place. AMCs could use this captive audience not just to negotiate for licenses for future machine-learning products (as some are currently doing 16 ) but also to protect and improve the treatment of their patients and participants. Part I of this article will discuss the value of secondary research with data and specimens. Part II will analyze why AMCs have been put at a disadvantage as compared to industry in amassing the large datasets that enable this work. It will speci cally focus on the origin of the human subjects research regulations, their scope, regulatory alternatives for industry dataset governance, and the increasing mixture of health data and specimens across entities. Part III will explore the limitations of this current governance structure, arguing that the federal regulations are not accomplishing their stated goal of informed consent, and they are also not appropriately calibrating to the risks and bene ts of secondary research. In addition, the regulations as written are serving to actually encourage a private data and specimen market with associated limitations. And Part IV will propose that, moving forward, AMCs should set their own standards for commercialization of the data and specimens they generate in-house, the ability of their researchers to use industry data for their own work, and baseline informed consent standards for their own patients and participants.

The human subjects research governance structure was created to govern research with humans. It was not designed to govern research with all the stu derived from them. The consequences of this imbalance between emerging research protocols and static regulations is the government-enabled privatization of one of our most valuable health resources. But there are steps that AMCs can and should currently take to better control the revolving door of data and specimens between AMCs and industry to protect access to the data and specimens needed for life-saving research moving forward.

In order to achieve promises made by the Precision Medicine Initiative and other cutting-edge health campaigns, researchers need data-regarding lifestyle choices, environment, health outcomes, and genetics-derived from biospecimens, medical records, wearable technologies, and other collection methods. Through 'big data' researchers can slowly piece together what health outcomes individuals can control, or clinicians can treat, and subsequently improve. 17 This has led some scholars to 16 Dinerstein v. Google, LLC, No. 19 C 4311, 2020 WL 5296920, 1079 (N.D. Ill. Sept. 4, 2020) ('Whatever a perpetual license for "Trained Models and Predictions" actually means, it appears to qualify as direct or indirect remuneration.'). 17 Anne Cambon-Thomsen, The Social and Ethical Issues of Post-Genomic Human Biobanks, 5 N . R . G . 866, 867 (2004) ('large population biobanks are indeed useful tools not only as a repository of genomic knowledge but also as a means of measuring non-genetic environmental factors. As such, they give epidemiologists and geneticists a new tool to explore complex gene-gene and gene-environment interactions at the population level.'). categorize health data as critical 'infrastructural resource'; its value derived from downstream uses rather than as an end product in and of itself. 18 Ruth Faden and colleagues have argued that medical centers should be reconceptualized as 'learning health systems' which would 'have continuous access to information about as many patients as possible to be e cient, a ordable, fair, and of highest quality.' 19 But data and biospecimens currently used for secondary research o en come from broader sources than a single medical center. 20 Personal health data are collected across the Internet, apps, and other data-capture mechanisms via algorithmic systems in people's devices, wearables, homes, work, personal lives, and leisure activities. 21 This makes big data a big business. 22 In 2017, the personal data market was valued at $35 billion-and it is projected to reach $103 billion by 2027. 23 Resources that are bene cial to a large part of the population, such as natural resources like fresh water or man-made resources such as data or biobanks, are o en described as 'common resources' . A unique set of theories regarding the best ways to govern these resources has direct applicability to the health data and biospecimen commons. 24 An o -invoked example of a commons is a shared pasture upon which sheep may graze. If sheep overgraze, the grass will diminish, and no sheep will be able to graze. Thus, although any individual farmer might bene t from adding to her ock and allowing an additional sheep to graze, if all the farmers acted in such a way inde nitely, there would be no grass le for any sheep and everyone will be worse o . As Garett Hardin 25 originally argued:

Therein is the tragedy. Each man is locked into a system that compels him to increase his herd without limit -in a world that is limited. Ruin is the destination toward which all men rush, each pursuing his own best interest in a society that believes in the freedom in the commons. Freedom But how to avoid such ruin? Hardin o ers two solutions: privatization or government regulation ('These, I think, are all the reasonable possibilities. They are all objectionable. But we must choose -or acquiesce in the destruction of the commons . . . .'). 27 In other words, if the government is not governing a commons adequately, private interests will. Thus, under social contract theory, communities are incentivized to give up some amount of their liberty in exchange for living within a system that o ers centralized protection for community well-being. But, although private industry 'may well contribute to the common good' they 'are not guardians of this common good.' 28 The common good is not a private matter, it is the purview of government. 29 So then what should we do as a society if the government is not adequately protecting it?

In order to fully discuss potential solutions to balancing the breadth and value of industry versus AMC secondary research banks, we must rst understand how they are currently governed. This section will review the current human subjects research regulatory structure, discuss limitations inherent therein, explore alternative regulations potentially applicable to industry databanks, and end by arguing that-while the entire system is founded on controlling the entity that acquired the health data or specimen in the rst place-data and specimens are becoming increasingly mixed across entities, thereby undermining a central premise of the entire governance system.

The current US human subjects research regulations were developed in the 1970s and '80s in the wake of research catastrophes, such as the infamous syphilis experiments in Tuskegee, Alabama conducted by the US Public Health Service. 30 These regulations are steadfastly founded in the need for the informed consent of the individual, 31 as a demonstration of her autonomy interests, before she may be enrolled in research as a participant. Case law focused on secondary research use of data and specimens, however, narrowly assesses them on their value to research-as opposed to the individual from whom they were derived. However, new cases regarding modern data-sharing relationships between AMCs and industry may begin to elucidate how the law will attempt to control these kinds of relationships moving forward. home, 33 there was still an overarching sentiment by the federal government that US clinical researchers were upstanding citizens, just like their clinical counterparts, and their motivations should generally not be questioned. 34 This assumption was challenged in the 1970s with the public revelation of the now-infamous syphilis experiment in Tuskegee, Alabama. 35 During that experiment, researchers from the US Public Health Service lied to impoverished African American men with syphilis, whom they went on to study without notice or consent. In 1932, when the syphilis experiments in Tuskegee began, the only known treatments for syphilis (eg arsenic or mercury) required a long course, were largely ine ective, and had many adverse e ects. 36 However, in 1943, the same team of Public Health Service researchers discovered that penicillin could e ectively cure syphilis. 37 The syphilis experiment in Tuskegee then took an even darker turn when researchers began attempting to prevent subjects from accessing penicillin that might treat their syphilis . . . for the next 30 years. 38 It was not until an internal US Centers for Disease Control and Prevention whistle-blower and a journalist brought the syphilis experiment in Tuskegee to the attention of the US media in 1972 that the study was nally stopped. 39 In addition, once discovering a cure for syphilis, many of the same researchers turned to improving prophylactic measures to prevent it in the rst place, and conducted experiments between 1946-48 in Guatemala for which they purposefully infected vulnerable subjects with STDs. 40 The experiments in Guatemala 33 Henry K. Beecher, Ethics and Clinical Research, 274 N. E J. M . 1354 (1966) ('Human experimentation since World War II has created some di cult problems with the increasing employment of patients as experimental subjects when it must be apparent that they would not have been available if they had been truly aware of the uses that would be made of them. Evidence is at hand that many of the patients in the examples to follow never had the risk satisfactorily explained to them, and it seems obvious that further hundreds have not known that they were the subjects of an experiment although grave consequences have been su ered as a direct result of experiments described here.' were kept secret until rediscovered in 2010. 41 The US clinical research system clearly su ered from critical aws in oversight with terrible consequences. 42

In the face of such interventional research failures-with risks and burdens to subjects that were individual, physical, and profound-US bioethicists and regulators reconsidered treating clinical researchers with the same deference given to clinicians. Instead of presuming that the motivation of a researcher was bene cence, regulators instead began to emphasize the potential con ict of interest a researcher has with promoting her own work. Under this view, proposed research protocols had to be assessed by neutral third parties in order to protect the participant from the con icted researcher. The role of the third party would be to ensure that any potential risks of research were counterbalanced by potential bene ts (either to the individual or society) and that individual subjects provided fully informed consent before enrollment. The Belmont Report, authored by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research in 1979, thus cemented autonomy's preeminence as the cornerstone of clinical research ethics. 43 Ironically, although the syphilis experiment in Tuskegee was the inciting incident for the Belmont Report, one of the framework's main takeaways-that participants should give informed consent to participation in research-would not actually have resolved the profound problems with that work. 44 Although researcher deceit in Tuskegee was surely a great moral defect, even if the participants had consented the experiment should never have taken place. There was also irreconcilable bene cence and justice de cits (the other two Belmont principles) as the potential bene ts of the study were not proportional to the risks undertaken and the study targeted impoverished and uneducated Black participants for research that was not intended to speci cally help them or their community.

But there is a policy advantage in the regulations' focus on informed consent. 45 Generating a list of consent form disclosure requirements to be presented to prospective enrollees is an easier goal to achieve than writing the rules that somehow assure justice and fairness. The government thus codi ed the predominance of disclosure, framed as supporting the informed consent necessary to enable autonomy, into the foundation of the human subjects research governance structure. The rst subpart of these regulations were later adopted across the majority of the US federal departments and agencies and thus named the 'Common Rule' . 46 The Common Rule generally requires Institutional Review Board (IRB) review of proposed protocols to ensure there is an appropriate balance between risks and burdens to participants and potential bene ts to the participant herself, or to knowledge generally. There are additional protections for vulnerable populations, such as children, in subsequent subparts. 47 If an IRB has authorized recruitment of participants into a study, individual consent must be given by the individual participant or her representative. 48 And detailed consent form disclosures-such as information about risk, bene ts, and alternatives 49 -now act as the gatekeepers through which all generalizable knowledge must pass. Considerations of justice and bene cence are le to the mercies of individual IRBs to assess on a case by case basis. 50 The Common Rule had remained substantially similar to its rst iteration until 2019 when it was revised a er a 6-year regulatory notice and comment process. 51

Although regulatory protections for human subjects research has largely focused on the scope of which participants should be protected, much of the famous human subjects research case law has focused on use and access to biospecimens via the classic trio of Moore v. Regents, 52 Greenberg v. Miami, 53 and Washington University v. Catalona. 54 Together, these cases are less deferential to the autonomy interests of the people from whom the specimens are derived, and are instead founded in supporting researcher access to valuable biobanks. The new dismissal in Dinerstein v. Google 55 demonstrates how some of these issues surrounding data sharing speci cally might be litigated henceforth.

In Moore v. Regents (1990) , patient John Moore went to doctors at the University of California, Los Angeles for the treatment of his hairy-cell leukemia. His clinicians collected many types of biospecimens from him, including samples taken a er such collection was no longer necessary for his clinical care, without disclosing that the purpose of the ongoing collection was research. to develop a lucrative cell line from his specimens. Once Moore realized what his doctors were doing, he sued for conversion (among other things). 56 The California Supreme Court found that a claim of conversion could not stand because Moore did not retain an ownership interest in his cells once they le his body. It did nd that the doctors should have disclosed their research interest to Moore as a potential con ict of interest during his clinical informed consent process. 57 The court ultimately held that 'the theory of liability that Moore urges us to endorse threatens to destroy the economic incentive to conduct important medical research. . . . If the use of cells in research is a conversion, then with every cell sample a researcher purchases a ticket in a litigation lottery.' 58 In Greenberg v. Miami (2003) , 59 parents of children a ected by Canavan disease, a devastating neurodegenerative disorder, donated money, medical information, and biospecimens to researchers at Miami Children's hospital. The families stated that their goal was to support the research necessary to isolate the variants associated with (and thereby develop a carrier test for) the disease, as well as work toward a cure. The Miami researchers did in fact identify the variant associated with Canavan, but patented the discovery. 60 The patent restricted others' ability to o er Canavan carrier testing or do their own therapeutic research.

The families sued for claims including a lack of informed consent and conversion based on their understanding that their contributions were in exchange for 'a ordable and accessible' testing for other families. 61 The district court in this case declined to recognize a failure in the duty of informed consent between the families and the researchers. The Greenberg court distinguished Moore due to the 'therapeutic relationship' between Moore and his physician researchers; in Greenberg the court described defendants as 'solely medical researchers' . 62 The court bemoaned that nding otherwise would 'have pernicious e ects over medical research . . . .' 63 The conversion claim was also dismissed since 'the property right in blood and tissue samples also evaporates once the sample is voluntarily given to a third party' . 64 In Dr Catalona sent a letter to the much broader cohort of all (∼30,000) contributors whose specimens had been used in his research asking them to donate and release their samples to him at Northwestern for use 'only at his discretion and with his express consent . . . .' Six thousand agreed. 67 WashU sued.

The Missouri district court found for WashU in part with reference to Moore and Greenberg, 68 and in so doing made an impassioned policy argument for the importance of enabling accessible biobanks:

Medical research can only advance if access to these materials to the scienti c community is not thwarted by private agendas. If le unregulated and to the whims of a [research participant], these highly prized biological materials would become nothing more than chattel going to the highest bidder. It would no longer be a question of the importance of the research protocol to public health, but rather who can pay the most. [ . . . ] The integrity and utility of all biorepositories would be seriously threatened if [research participants] could move their samples from institution to institution any time they wanted. No longer could research protocols rely on aggregate collections since individual samples would come and go. 69 A more recent example related to data-sharing agreements between an AMC and industry comes in the form of Dinerstein v. Google 70 from the Northern District of Illinois. At issue in Dinerstein is a 2017 data use agreement between the University of Chicago and Google. The goal of this agreement was to generate 'machine-learning techniques to create predictive health models aimed at reducing hospital readmissions and anticipating future medical events' . 71 To do so, UChicago shared the 'de-identi ed' electronic medical records (EMR) of all adult patients over a 5-year period (the data, in fact, included dates of service). 72 When Mr Dinerstein, a patient, found out his health data had been shared with Google, he sued for breach of contract (among other things) 73 for alleged violations including HIPAA compliance (as the court allowed a private right of action for HIPAA under a state tort law claim 74 ). 75 Under HIPAA, covered entitles may not generally sell protected health information (PHI) without written permission. But this prohibition does not include sharing PHI for research purposes in exchange for a 'reasonable cost based fee to cover the cost to prepare and transmit' said PHI. 76 Models and Predictions' created by Google. 77 Defendants argued that the perpetual license was, in fact, only a reasonable cost-based fee. However the Court found that: 'Whatever a perpetual license for "Trained Models and Predictions" actually means, it appears to qualify as direct or indirect remuneration.' 78 But ultimately the Court ruled that none of Mr Dinerstein's arguments could support a claim for relief 79 because Illinois neither recognizes noneconomic breach of contract damages, eg 'anxiety and distress' (but for under exceptional circumstances), 80 nor could the plainti establish economic damages to his EMR data (which were not even recognized as his property to begin with). 81 In summary, it will be exceptionally hard for plainti s to move past dismissal in the future unless they can establish that the invasion of their privacy resulted in speci c nancial injury.

Despite the rich regulatory and case law background of the governance of human subjects research, a major limitation is that this governance structure does not actually cover all human subjects research. Even where the regulations do apply, they only govern research that is interventional or involves identi ed biospecimens or datawhich excludes a large number of secondary protocols. And, even when the regulations apply, and even if the biospecimens or data are identi able, there are still options for conducting the research with a waiver of informed consent. As Neil Richards and Woodrow Hartzog have argued: consent 'transforms the moral landscape between people and makes the otherwise impossible possible' . 82 But the human subjects research regulations allow an exceptional number of exceptions to actually procuring such consent.

First, the human subjects research regulations do not actually apply to all human subjects research. There are, in fact, only four circumstances in which they do apply: (i) If the investigator is conducting research using federal funding from a US Department or Agency that has adopted the Common Rule. 83 This is understood as a reasonable derivation of Congressional spending power, ie if you are going to take the government's money to do research, it has the right to put limits on usage. 84 trials at US institutions that receive some federal support for human subjects research (regardless of the funding of the speci c study). 85 But the nal iteration of the updated rule did not extend its scope. 86 (ii) If an institution voluntarily decides to extend the regulatory requirements to all of its employees conducting human subjects research (as many do). 87 (iii) If researchers are using an investigational-only product which requires US Food and Drug Administration (FDA) authorization to ship and use in interstate commerce. 88 Or (iv), if investigators wish to submit data derived from their research to FDA in support of an application for research or marketing, they have to follow substantially similar FDA regulations regarding the protection of human subjects. 89 These limitations mean that privately funded research is outside the scope of federal regulations if it does not involve product requiring FDA authorization to distribute or if researchers do not ultimately submit their data in support of an FDA application. 90 Some private entities may choose to follow components of the research regulatory structure due to other market motivations, 91 discussed further below, but many do not. Recent more comprehensive data privacy legislation has been adopted in Europe 92 and California, 93 although both still only regulate 'identi ed' data, have ambiguously broad exceptions for research in public health, and do not cover health-related data sharing in the USA. 94 For example under the GDPR, although participants in clinical trials must give full informed consent for future data sharing ('organization employed clear, intelligible, and easily accessible language, with the purpose for data processing attached to that consent' 95 ), and they must be able to withdraw from future trials, they cannot retrospectively erase their clinical data without an audit trail. 96 In addition, and somewhat counter-intuitively, research with health data and specimens collected via clinical care from patients is also not governed by the human subjects research regulations. This work instead falls under the HIPAA research rules. But HIPAA only covers individuals' PHI collected by 'covered entities' (ie health care providers, health plans, or healthcare clearing houses). Covered entities are allowed to share identi ed data with 'business associates' with whom they have a contract to perform 'functions or activities on behalf of' or provide services. 97 HIPAA allows entities to transfer data for research as long as they are deidenti ed, 98 but also allows for the research sharing of identi ed data and specimens with an IRB waiver-a much more e cient process then acquiring consent in the rst place. 99 And the mandatory disclosures regarding default consent to data and specimens collection for research is generally written right into an institution's standard clinical consent form. 100 As W. Nicholson Price II has pointed out:

' . . . if health privacy is worth defending, then why limit those defenses to the narrow set of actors and data covered by HIPAA, as the United States largely does? HIPAA's outdated focus on covered entities and its safe harbor for "deidenti ed" data leave too much for manipulation, if health privacy protection is the goal.' 101 But, as tested in Dinerstein v. Google, 102 built into HIPAA is the assumption that private health information is only collected by covered entities, or, that once collected, those data stay put. 103,104 In addition, HIPAA neither envisioned nor protects the huge swath of health-proxy data from which entities can derive health-related information 95 In the big-data world, the type of data sources covered by HIPAA are but a small part of a larger health data ecosystem.').

(eg Google's non-UChicago derived health information). 105 This might include, for example, geolocation data about visits to a psychiatrist, or demographic information o en correlated with health outcomes such as maternal mortality. 106

A second important limitation of the research regulations is that-even if research is federally funded, at an institution that requires all researchers to follow them, or generated with or as part of an FDA application-the rules only apply to research involving 'human subjects' . 107 A 'human subject', in turn, is de ned as a living person with whom the investigator 'obtains information through intervention or interaction' or which involves 'identi able private information or identi able biospecimens' . 108 Thus, whether a biospecimen or data are considered 'identi ed' remains a critical threshold requirement for protections.

Past concerns regarding individual identi ability of data have focused on large-scale or germline genomic data. As such genetic sequences are unique to only one person, they were assumed to be more easily reidenti ed than other types of deidenti ed health data. 109 However, recent research has demonstrated that now almost all data from Americans can actually be reidenti ed by matching it with as few as 15 demographic attributes that are easily discoverable from the information we enter into our phones, computers, and wearables every day 110 (unless you are Latanya Sweeny, in which case you only need three 111 ). The time when genes represented a singularly unique identi er worthy of potential additional protection has already come and gone. Thus additional laws protecting people from untoward uses of those data, ie the Genetic Information Nondiscrimination Act of 2008, 112 are now far too limited in scope to 105 itself yields information about, but does not de nitively identify, a speci c individual. The individual still has "practical obscurity", as his or her identity is not readily ascertainable from the data. Practical obscurity means that simply because information is accessible, does not mean it is easily available or interpretable, and that those who want to nd speci c information must expend a lot of e ort to do so . . . . In addition, even if we know that a whole genome sequence is from one individual, we cannot know which of the over 7 billion people on Earth that person is without a key linking the whole genome sequence information with a single person or their close relative. Therefore, while whole genome sequence data are uniquely identi able, they are not currently readily identi able.') ( 16 • Governing secondary research use of health data and specimens protect people from the myriad types of health data which may be linked back to them in discriminatory ways. 113

Last, it is worth noting that even if research falls within the scope of federal regulation and even if participants fall within the de nition of 'human subjects', researchers may still apply for a waiver of informed consent. Waiver can be granted by an IRB if the research involves no more than minimal risk, could not otherwise be practicably carried out, would not adversely a ect the rights or welfare of participants, and if additional relevant information will be provided to subjects a er their 'participation' . 114 Thus, despite the enormous research governance system set up by the federal government; parallel research protection programs at individual research institutions; and complex review, waiver, and exception policies with which researchers must grapple; many instances remain where informed consent of individual participants is not legally required to begin with. According to Price, ' . . . privacy hurdles are just thathurdles, not walls. They can be surmounted' . 115 The world of 'aconsensual' 116 secondary research is still vast.

Despite not being generally covered under the human subjects research regime, the private human health data market has been in uenced, however circuitously, by FDA via its involvement in the direct-to-consumer personal genetic testing (DTC-PGT) industry. Although FDA has authority over a broad swath of drug, device, and biologic products including genetic tests, it exercised 'regulatory discretion' over DTC-PGT industry from its inception in 2007 until 2010. 117 But, in 2010, Pathway Genomics, the largest DTC-PGT player at the time, announced a partnership with Walgreens under which it would sell its product in stores across the USA (in contrast to its earlier more discrete online sales model). 118 FDA assessed that this increase in access to potential consumers increased the absolute risk of the product, 119 presumably because more individuals were likely to buy them and therefore more individuals would su er related burdens. FDA therefore sent 'Untitled Letters' warning of potential violations of the Food, Drug and Cosmetic Act to 23 DTC-PGT companies. 120 Untitled Letters did not require the companies to actually discontinue their product, most companies did. 23andMe, which had deep pockets due to its heavy investment from Google, 121 was the only DTC-PGT company le standing to begin regulatory authorization. 122 But 23andMe, somewhat disingenuously, continued to market its product . . . while seeking FDA authorization to market its product. By 2013, FDA sent 23andMe a 'Warning Letter' requiring the company to discontinue its health-related testing sales. FDA justi ed its response due to concern about the 'public health consequences of inaccurate results from the device.' 123 23andMe complied, withdrew its health-related testing from the market, and began to o er components again only after they became FDA authorized.

Although genetic data are but one area of health-related data making up large databanks, it is an important one. The FDA/23andMe saga is an example of how the government can e ectively regulate products within its purview. However, FDA's reach over DTC-PGT data was by proxy. What FDA actually has authority over is the genetic testing device and informational results returned to consumers, not the data or research itself. Regulating the secondary use of 23andMe's over 12-million person genetic and phenotypic database, 124 or Ancestry.com's 18 million one, 125 remains outside both the purview of FDA and DHHS.

Despite the fact that federal governance structure over health data and biospecimens focuses on controlling the actions of the entity that collects the data or specimens in the rst place, data and specimens are increasingly becoming mixed across clinical, research, and private entities a er collection-without additional informed consent. Speci cally, the sharing of data and biospecimens between academia and industry has been growing at a rapid pace. In addition to the deal already discussed in the introduction between Ascension and Google, where identi ed data are owing from a covered entity to a private entity (otherwise in the business of collecting widespread data about people) under a HIPAA business associate agreement; and the one at issue in Dinerstein v. Google, where EMR data were shared from UChicago to Google in exchange for licensing rights of future algorithmic decision-making tools; 126 Google also has major deals with Mayo Clinic, 127 the University of California, San Francisco (UCSF), 128 and Stanford Medicine. 129 Note that all of these deals actually involve patient (ie not research participant) data. Therefore, they are not primarily analyzed under the human subjects research regulations, but rather the more exible HIPAA research regime discussed above.

But, even if medical record information that is shared is fully deidenti ed, and therefore does not require a HIPAA business associate agreement (which would also include other proscriptions on use), with the amount of personal data Google has already collected regarding the average person, it would be fairly straightforward to reidentify someone's data and link their identity back to their medical information. 130 Mr Dinerstein attempted to use that argument in his case against Google (ie that there was a higher than average risk of reidenti cation of his EMR data by Google because of 'the information Google already possessed about individuals through the other services it provides' 131 ), but the Northern District of Illinois Court agreed with Google that the theoretical ability to reidentify the data, in the absence of evidence that it had actually done so, was not enough to demonstrate a violation. 132 Of note, the Google/UCSF agreement does speci cally allow Google to connect the otherwise deidenti ed health data with other 'data and materials it obtains elsewhere...' 133 Thus, ironically, Google may end up with more information about patients whose medical information was shared with them in a deidenti ed fashion than with patients whose medical information was identi ed in the rst place (i.e. with an accompanying business associate agreement limiting reidenti cation and linkage with other data).

In addition, academic researchers are also increasingly using data and specimens gathered by private industry (thus the 'revolving door' analogy). Indeed, the number of peer-reviewed publications using genetic data from a private databank increased from four in 2011 to 57 in 2017 (for a total of 181 over the time period). The vast majority struck a sweeping partnership with Google to store patient data in the cloud and build products using arti cial intelligence and other technologies to improve care.' of those publications (86%) listed at least one academic author. 134 In fact, the models trained by Google from the UChicago EMR data resulted in a publication in npj Digital Medicine with a rst and last author from Google and three academic researchers from UChicago (where the data were from) as well as UCSF and Stanford (which have other agreements with Google 135,136 ). Having data published in the peer-reviewed literature is itself a business asset for industry. Unlike some tangible common resources like sh in a lake, knowledge and ideas are not generally depleted by use. 137 In fact, the use of knowledge increases its value. 138 Publishing articles in the peer-reviewed literature also demonstrates the scienti c acceptability of a dataset. For example, in the beginning there were serious questions regarding the validity of self-reported phenotypic data, but 23andMe has established such collaborations as a viable research model. 139 23andMe publicizes these relationships and publications in order to recruit other research partners. 140 We can only speculate regarding why any one researcher might choose to partner with private industry rather than analyze data held by academia, a government entity, or recruit new participants. 141 But although they may be acting rationally as an individual, many researchers acting in this way can enhance private data resources at the cost of developing and supporting more accessible ones. If researchers continue to or increasingly rely on private datasets over re ning, validating, and contributing to other more accessible datasets with their own work-much like Hardin's overgrazing sheep 142they may unintentionally as a community contribute to the current environment in which accessible banks struggle to compete with the value and size of private sets. 143 This system contributes to the enabling of private databanks by AMCs either intentionally or unintentionally investing in, and validating, a structure which they do not ultimately control. In addition to scoping issues, there are several important limitations on the current governance structure of the secondary research market. First, despite extensive and complex informed consent requirements for federally-funded researchers, even when participants provide explicit consent, the result is not consent that is actually informed. Second, despite the recent revision, the regulations written for interventional human research are not tailored adequately for the risk/bene t pro les of secondary research. And third, the combination of the limitations and failures of the human subjects research market has enabled the privatization of this valuable resource-which has related limitations of its own.

A rst limitation of the current governance structure is that, even when research consent is obtained, it is o en not actually informed. 144 Although many have studied how to improve the informed consent process, the only intervention that has been found to consistently improve participant comprehension is a conversation between the prospective participant and a person knowledgeable about the study. 145 But the human subjects research regulations, while mandating that many speci c things be included in the informed consent form (eg descriptions of risks, bene ts, alternatives, con dentiality, compensation, contact information, voluntariness, and information regarding secondary research 146 ) say very little when it comes to the actual informed consent conversation. 147 The long lists of mandatory disclosures in research informed consent forms have diminishing returns. 148 Participants neither read nor understand them. 149 As Meg Leta Jones and Margot Kaminski recently argued:

The U.S. version of individual control and consent is largely understood to be a paper regime, based on long, elaborate privacy policies that nobody reads, and surveillance that is impossible to opt out of in practice. Thus 'consent' and 'notice and choice' have become somewhat dirty words in data privacy conversations, standing for the exploitation of individuals under the ctional banner of respecting their autonomy. 150 In addition, in a recent study of participants who enrolled in a precision medicine trial, the majority of participants had no idea that their data might be commercialized or used for secondary research protocols-mere weeks a er they had signed a comprehensive informed consent form disclosing just that. 151 It appears that the more information the regulations mandate be included in the informed consent form in the name of autonomy and transparency, the less likely participants are to actually read and comprehend it. 152 In secondary research-which o en involves complex technologies, ethereal risks, and vague protocols-these concerns are compounded. 153 As Laura Beskow has argued: ' . . . informed consent cannot bear the weight it is being asked to shoulder. There is a chasm between the theoretical ideals of informed consent and what it accomplishes in actual practice' . 154 And Patrick Taylor: 'We cannot assume that all social goals will be met through a lemming-like coincidence of universal consent' . 155 People have a hard time grasping the concept of risk in general. 156 And, although a primary risk of secondary research is reidenti cation, the concept of identi ability is itself a false-binary. 157 The risk of reidenti cation is on a spectrum of how much risk, which constantly evolves as additional databases are added to public accessibility and emerging aggregation and algorithmic technologies. In addition, people feel di erently about the risk of reidenti cation as it is related to di erent kinds of data. As Raymond De Vries and Tom Tomlinson argue: Donors need to know not only whether they can be reidenti ed; they also need to be able to decide whether the harms caused by reidenti cation are too high. The answer to that question depends on the type of research ndings being protected and the implications for the person's welfare should those ndings be disclosed, not just the statistical likelihood of reidenti cation. 158

Even for regulated research with myriad protections regarding informed consent, the laws only practically require documenting legal consent, as opposed to ensuring 151 Kayte Spector-Bagdady et al.

Perspectives on Commercialization of Precision Oncology Data 25 T O 620 (2020) ('Several patient-and clinician-participants did not understand that the consent form already permitted commercialization of patient genetic data and expressed concerns regarding who would pro t from the data, how pro ts would be used, and privacy and access.' 

consent that is actually informed. And that necessity to document can also lead to limiting research with important populations who could otherwise bene t from it, like cognitively impaired adults. 159 As Taylor has bemoaned: 'Ethics is reduced to autonomy; autonomy is reduced to naked choice; and a self-commodifying model of choice is substituted for richer visions of human nature and interdependence.' 160

A second problem with the current regulatory structure surrounding research data and biospecimens is that it was a system originally built to protect people from potentially harmful interventions, not secondary research. The regulations are therefore not calibrated to the unique risk-bene t pro les of secondary research, leading to both overand under-regulation. Also, the regulations' threshold for governance is still method of collection-which aligns with neither contributor concerns regarding usage nor current data-sharing practices.

of Secondary Research A major issue with the current governance of the federally funded secondary research enterprise is a lack of responsiveness to the risk/bene t pro les of most secondary research protocols. Not only does secondary research need large amounts of biospecimens and data in the aggregate to be helpful-distilling the value of any one participant-lowered risks to individuals, level of burden if those risks materialize, and greater bene ts to the community warrant a reconsideration of the current informed consent requirements. 161 With the transition from interventional clinical research to secondary research protocols, corresponding risks to participants have also shi ed. 162 Whereas the research violations that founded the current regulatory and case law structure were tangible and largely physical 163 or nancial 164 in nature, secondary research risks generally involve dignitary harms which are harder to quantify 165 and establish as damages in court. 166 uses of their data or specimens, even when they are never reidenti ed 167 (also related to the concept of a 'dignitary tort' in law, such as intentional in iction of emotional distress). For example, in one study by De Vries and colleagues, whereas more than 70% of participants surveyed said they would be happy to sign a 'blanket consent' for any future use of their donated biospecimen, when pressed speci cally about controversial examples of research-such as those involving patents, abortions, or weapons of mass destruction-almost as many changed their mind and asked to withdraw. 168 Last, the value of the denominator in research has shi ed considerably. In interventional clinical research, due to the intensive control of variants and attempts to ensure that the study is fully powered to capture statistically signi cant di erences, each participant can be of value to the study at the individual level. But in secondary research protocols participants are generally of value in aggregate. 169 This is analogous conceptually to the recognized 'prevention paradox' in public health, where changes in health behavior can positively a ect outcomes at the population level but only result in negligible improvements for any given individual. 170 On the bright side, due to this shi in value-and unlike, for example, the single cancer patient who may be enrolled in only one experimental chemotherapeutic or standard of care control arm-uses of aggregate data are generally 'non-rivalrous' or 'non-subtractive' of others' uses. 171 As Charlotte Hess and Elinor Ostom, the founders of modern common resource policy, have argued: ' . . . the more people who share useful knowledge, the greater the common good' . 172 Last, upon reviewing the new types of risks and bene ts for secondary research, an important overarching observation becomes evident. Although the risks of secondary research (eg privacy breaches, dignitary harms) remain remote, small, and individual, the bene ts (valuable datasets and knowledge outputs) redound to either the entity holding the data or the common good. 173 This situation is similar to the development of 'herd immunity' in the public health context, where for some diseases 90% of individuals must be vaccinated to achieve herd immunity of a community that otherwise protects those who cannot be vaccinated. The pursuit of herd immunity in vaccinations relies on social contract theory and requires individuals to take on some small risk to themselves (of adverse events associated with the vaccine) to bene t others greatly (by protecting them from the more harmful disease). Similarly, the asymmetry between the risk-and bene t-bearer can have detrimental e ects on an e cient secondary research biospecimen and data market. Market actors o en make decisions based on costs and anticipated bene ts for themselves, and disregard or discount costs to others. This 'negative externality', 174 of researchers discounting privacy risks to the participants of secondary research protocols, can cause the secondary research market to become ine cient, ie not fully tally the actual costs and bene ts of an action-unless externally forced to perform otherwise.

Another problem with the current governance of the secondary research enterprise is that siloed regulation of data and biospecimens by collection entity no longer makes sense due to increased sharing. This is why the new data regulations in both California and Europe generally regulate by the kind of data being used, rather than by who is using it. 175 Also, in the USA, who collected the data is an irrelevant distinction to contributors who generally care about its use.

There has been a plethora of empirical studies demonstrating that people care how their data and specimens are used for research. 176 A minority even worry about research with deidenti ed data and specimens, which is particularly true in Black and Latino populations, 177 and currently out of scope for all regulatory regimes. In addition, although many people hypothetically support the use of specimens in research, 178 biobanks are increasingly turning to a 'commercialization' model in order to support the expenses of long-term cryopreservation. 179 But a recent US-based study found that 67% of participants wanted to be clearly noti ed regarding potential biospecimen commercialization and only 23% were comfortable with such use. 180 The revisions to the Common Rule now require that regulated researchers disclose potential commercialization to participants, putting them at a potential additional disadvantage for recruitment as compared to their unregulated peers. 181 As aptly summarized by the recent National Academy of Medicine (NAM) report 'Health Data Sharing to Support Better Outcomes: Building a Foundation of Stakeholder Trust':

The patient and family community lacks trust that health care systems and researchers will make data and the conclusions based on those data available to them and will not misuse data they provide by rationing care and sharing it with unauthorized third parties. 182 And last, even if the regulations are applicable and consent is obtained, it does not provide the kind of control that contributors want. The Common Rule or HIPAA only provide a binary 'exit right'-the right to either contribute to research or not. 183 Participants are not given a voice in the kind of research gets done or veto power over what secondary research protocols they are or are not willing to contribute. 184 As Richards and Hartzog argue: ' . . . consent does not scale. It is almost entirely incompatible with the modern realities of data and technology in all but the most limited of circumstances' . 185

A third major problem with the current governance of the secondary research market is that it actually enables the privatization of secondary research data and biobanks. And privately-held databanks, as opposed to those run by a government agency or other type of accessible collaboratory, are associated with several pressing societal and scienti c concerns.

As discussed above, the proposed alternative to governance of shared resources in the 'tragedy of the commons', other than government regulation, is privatization. As Michael Heller and Rebecca Eisenberg pointed out (as far back as 1998), this is the direction biomedical research is headed. 186 But it is not fair to assume that the privatization of a shared resource is necessarily bad. According to Hardin, it is the only other option in averting sure ruin. 187 The US federal and global governments have focused vast resources into encouraging data accessibility and sharing. The European Open Science Cloud and various country-speci c genetic and other health data and specimen banks have aggressively 182 NAM, Health Data Sharing to Support Better Outcomes: Building a Foundation of Stakeholder Trust (2020) https://nam.edu/health-data-sharing-special-publication/ (accessed Jan. 28, 2021). 183 Evans, supra note 4, at 684 ('These federal regulations conceive individual protection as an exit right (informed consent/authorization) while granting people no real voice in setting the goals of informational research or the privacy and ethical protections they expect. Lacking a voice, people CRexit from researchthat is, they exercise their Common Rule, or "CR", informed consent rights to exit from informational research altogether. This CRexit strategy scarcely advances people's interests, when surveys show that most Americans would like to see their data used to advance science.'). 188 The NIH's 2018 Strategic Plan for Data Science proposes a 'data ecosystem' which would allow for 'a distributed, adaptive, open system with properties of self-organization, scalability and sustainability' via projects including the NIH Data Commons. 189 However, these initiatives have yet to achieve widely engaged data-sharing practices. 190 A decade ago, the NAM report Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease argued:

Data-sharing standards should be created that respect individual privacy concerns while enhancing the deposition of data into the Information Commons. Importantly, these standards should provide incentives that motivate data sharing over the establishment of proprietary databases for commercial intent. Resolving these impediments may require legislation and perhaps evolution in the public's expectations with regard to access and privacy of health-care data. 191 This report, in turn, inspired the US government's dedication to building a health biospecimen and data commons, the All of Us Research Program, which was announced by President Barack Obama in his 2015 State of the Union address. The goal of All of Us is to 'enroll at least 1 million persons who agree to share their EMR data, donate biospecimens for genomic and other laboratory assessments, respond to surveys, and have standardized physical measurements taken' . 192 It supports ∼270,000 participants, and recently started returning a rst round of genic results to participants recruited by the University of Wisconsin. 193 All of Us targets recruitment to those historically 'underrepresented in biomedical research', and it currently boasts 75% of participants that meet that categorization. 194 Since 2015, Congress has allocated $1.02 billion toward supporting the All of Us program and the 21st Century Cures Act authorized another $1.14 billion through 2026. 195 By contrast, the DTC-PGT company 23andMe has a genetic database of over 12 million participants and counting, as well as over a billion phenotypic data points. 196 This makes it 'the largest re-contactable research database of genotypic and phenotypic information in the world.' 197 And 23andMe recently announced plans to go public with a merger valuation of $3.5 billion. 198 Therefore, despite All of Us' laudable goals and progress, the US government has essentially spent $2.16 billion to build a database to compete with the private ones its own regulations enabled in the rst place.

There are costs associated to allowing a valuable common resource to become privatized. First, informed consent is lacking at an even greater scale. Second, when data and biospecimens are privately held, industry can put limitations on access that might sti e future research advances. Third, without data access, peer researchers can neither validate nor build on work otherwise available in the peer-reviewed literature. Last, even if certain industry players are currently allowing limited researcher access to their datasets, a new business focus, leadership, or regulation could change that arrangement quickly-and the time and e ort other researchers spent contributing to and validating that private resource could be lost.

First, issues with the Common Rule's informed consent process can be compounded in unregulated industry research which generally relies on digital consent platforms (if it acquires consent at all). This type of consent to private consumer interactions is not a typical clinical or research informed consent with associated duciary obligationsit is contractual. 199 There is generally no IRB ensuring that the risks and bene ts are adequately balanced before attempting to enroll participants, but rather an attorney (best-case scenario) who has wordsmithed language to protect her company from liability and grant them latitude. Richards and Hartzog highlight three conditions that might make electronic consent particularly 'pathological': (i) when people are asked constantly for their consent such that there is not enough time to seriously consider each choice, (ii) when the risks of consent are complex and ethereal, and (iii) when people are incentivized to not take choices seriously 200 -all of which are relevant to the e-consent of unregulated research.

People also generally do not think about inputting their health data into private platforms, such as 'wellness apps' or industry websites, as commercializing their own information. 201 Almost a quarter of US adults report that they are asked to agree to a private privacy policy on a near daily basis. 202 Only 1/1000 consumers click on a website's terms of service; only 1/10,000 if it requires two clicks. For the very few who make it to terms of service, the median time spent reading them is 29 seconds. 203 Contemplating sharing sensitive health data does not change this. 204 And, even if consumers do glance at the terms and conditions, the risks of secondary usages of data are so complex that there is disagreement regarding whether terms and conditions governing them should even be considered valid. 205 This also explains contributor concern in the summer of 2019 when 23andMe announced its exclusivity agreement with GlaxoSmithKline to use its database for drug research and development (despite the fact that such a potential collaboration was laid forth clearly in 23andMe's Terms and Conditions). 206 In addition to the fact that most people do not read informed consent forms-and even if they do, comprehension is likely eeting-people are also generally unaware of the possibility of 'data mosaicking' (combining di erent datasets to gain a more complete picture of a single point of interest):

Our consent to data practices is astonishingly dispersed. Thousands of apps and services ask us for small, incremental disclosures, few of which involve the kind of collection of information that might give people pause. While dating apps and platforms that collect sensitive and large amounts of personal data might cause some pause, it's not as though people share all their information at once. Instead, it trickles out over time, such that people's incentives to deliberate at the point of agreement are small because we don't know how much information we will ultimately end up sharing. 207 Indeed, companies that create 'shadow health records' have started to multiply and gather health-related and proxy data from nonprotected sources, assemble the data back together under the identity of the individual from whom it came, and then sell access to the Frankenstein-ed health records back to researchers. 208 And, although the bene ts of digital consent are generally immediate and obvious (eg a funny picture of you as the opposite gender, or 30 years older, to share on social media 209 ), deidenti cation and mosaicking risks are o en unknown, complex to grasp, and may or may not become actual burdens. 210 Few understand that researchers will not just have the ability to access to your 'sel e', but connect it with troves of other data you share-inde nitely. A recent example of this is predators collecting name, birthday, and location information from people posting photos of themselves with their COVID-19 vaccination cards for potential scams or the sale of fake cards. 211 A second issue is potential limits on access. Researcher use of private datasets allows industry a gatekeeping function over what research is enabled. 23andMe has an internal committee that reviews proposed protocols and only supports a select few per year. 212 But gatekeeping can compromise the reliability of peer-reviewed literature and bias it in favor of industry. In 2011, for instance, 96.5% of published, industrysponsored, head-to-head comparative e ectiveness trials found favorable results-a highly unlikely outcome, presumably associated with the type of reports submitted for publication. 213 These kinds of access issues are already well-documented in the medical drug market. 214 But, as biospecimens and health data emerge as increasingly critical to drug and device development, 215 it is reasonable to anticipate similar problems in the upstream data market.

Third, if datasets are private, other researchers' ability to validate the work or build derivative discoveries will be limited. For example, there has been a recent rash of reanalyses of studies in the nutritional 216 and psychological literature 217 which has debunked many major studies-a critical re-examination opportunity that supports the integrity of science in the published literature. As argued in the recent NIH Policy for Data Management and Sharing: 30 • Governing secondary research use of health data and specimens

In fact, two COVID-19 drug studies from the same authorship team were recently retracted from the New England Journal of Medicine 219 and The Lancet 220 , respectively due to a lack of author-access to privately-held data-a fact which authors misrepresented when submitting the articles and con rming data validity.

Without access to underlying data sources, this type of post-hoc quality assurance is much harder, if not impossible. 221 And, as Heller and Eisenberg argued, too many intellectual property rights in premarket 'upstream' research can result in limited 'downstream' produce-oriented research in the 'tragedy of the anti-commons' . This type of tragedy can, in turn, lead to underutilization of a valuable resource. 222 Although norms are beginning to shi gradually, extensive disclosure of raw data in supplements to publications remains uncommon. If an external researcher were later to request underlying data from the corresponding author for veri cation or further research, the response to such query would also generally not be public (and there are many reports of data actually being notably unavailable upon request). 223 This tension is exacerbated when the underlying dataset has commercial value. 224 But, even if databanks are not protected by patents or other types of business interests, and even if corresponding authors would be willing to share the underlying datasets supporting their work, the burden of requesting and accessing the dataset is still on other researchers:

. . . when it is easy for owners to exclude users from access to resources, as in the case of 'practically excludable' materials and data, the burden of inertia is on users to persuade owners to permit access, whether or not the resource is covered by formal property rights Anne Wojcicki attributed it to privacy concerns surrounding use of their databank by law enforcement a er the GEDmatch saga. Sales of the 23andMe product have continued to decline (by $136 M just from 2019 to 20), and last year 23andMe laid o 14% of its employees. 240 Wojcicki attempted to head the generalization of GEDMatch privacy laxness o by coauthoring a new Privacy Best Practices for Consumer Genetic Testing Services 241 within months of the GEDmatch news and in the same week she announced the 23andMe deal with GlaxoSmithKline. 242 23andMe was joined on these Best Practices by several other major DTC-PGT players including Ancestry and Helix. 243 Self-regulation also has the potential to be more e cient and nely tuned to market variance than external regulatory bodies. 244 Evolving technology moves faster than notice and comment rulemaking allows. Evocative of when FDA nally intervened with the DTC-PGT market and all other companies but for 23andMe dropped o the market or began requiring a prescription, Maurer points out:

. . . o cial regulation can be oversupplied so that politicians and bureaucrats invest more than what the entire industry is worth to society. By comparison, society's investment in private regulation can never exceed what consumers are willing to pay for the regulated product. 245 That is, if industry spends more money on self-regulation that it can regain in sales, an e cient market would right itself by expelling such a product (23andMe was able to avoid this market consequence via its investment by Google). In addition, as argued by the recent NAM report on health data sharing:

There are some successful examples of health industry self-governance. The Pharmaceutical Research and Manufacturers of America's (PhRMA) Code on Interactions with Health Care Professionals brings additional clarity and speci city to existing FDA regulations and the antikickback law regarding incentives from pharmaceutical sales representatives to health care professionals (eg specifying that acceptable 'gi s' must be educational in nature). 247 In return, the government has acted creatively to incorporate PhRMA's perspective and exibility into governance by stating that compliance may protect companies from liability 248 or even requiring PhRMA Code compliance in settlement or corporate integrity agreements. 249 However, the private data and biospecimen industry has yet to attempt comprehensive self-regulation. The closest example is the 23andMe-driven DTC-PGT industry's recent Privacy Best Practices for Consumer Genetic Testing Services discussed above. 250 But, most DTC-PGT companies did not actually sign it, and the statement's scope had notable limitations including a lack of privacy protections for nongenetic health data also collected. 251 Thus, although self-governance is a potentially e ective possibility for the private data and biospecimen industry, it has not yet come to fruition despite decades of concern. Also, as Maurer concludes, 'this bargain is only available provided government can trust the private process', 252 and there is no indication that is true.

The broad limitations in scope and application of the federal human subjects research regulations put federally funded researchers at a competitive disadvantage vis-à-vis private industry, so much so that AMCs are increasingly buying their data from industry to begin with. 253 In lieu of national standards, it is time to look to regulatory alternatives to controlling the market, and-given their large negotiating power-the most promising seems to be AMCs setting higher policy standards.

A major value of private data and biobanks is in their ability to support good upstream research that can be translated into potentially lucrative downstream products with marketing authorization that clinicians will both use and prescribe. 254 of comprehensive databanks require a diversity of both genomic and other healthrelated data, o en found in EMRs. EMRs are generally in possession of hospitals and clinics providing health services. 255 This gives AMCs negotiation power-not just for licenses for eventual machine-learning products such as in Dinerstein v. Google, 256 but also to protect and improve the treatment of their patients and participants. Industry also needs AMCs to conduct and engage in research, publish articles, and treat the patients and write the prescriptions that make the private data valuable in the rst place. Although academia can also bene t from using data and specimens held privately (as it might be more cost-e ective for federally-funded researchers to purchase such data resources than generate them de novo 257 ), instead of waiting for industry to self-regulate its production of valuable health data and biospecimens, academia should self-regulate its own consumption.

In addition to the opportunity to potentially set better standards for the future, academia might also be motivated to set policies for engagement with private industry given the recent proliferation of related negative press coverage and lawsuits. 258 Nontransparent academic/industry partnerships can bring attention to that which is legal, but not widely known (eg the Mayo/Google deal), or that which is questionably legal to begin with (eg the Google/Ascension deal). Both types of engagement raise questions of potential corruption, which can in turn 'undermine[] the institution's e ectiveness by diverting it from its purpose or weaken[ ] its ability to achieve its purpose, including . . . the public's trust in that institution or the institution's inherent trustworthiness' . 259 But partnerships between industry and entities hoping to remain publicly oriented might raise a specter of corruption. As Jonathan Marks recently argued in his book, The Perils of Partnership, the focus of industry is pro t and branding. This focus in uences most, if not all, of industry's actions-which may 'lead to a bias toward the development of technological solutions to public health problems that may be readily commercialized' . 260 For example, when so drink companies partnered with public health agencies to jointly combat the 'obesity epidemic', the clinical focus was shi ed from the e ects of sugar to those of exercise; ie instead of focusing on limiting sugar intake, the pro ered industry/government partnership solution was increasing physical activity to burn it o . 261 Such partnerships not only allow industry to align government e orts on goals congruent with their bottom line, but also allow them to don a 'health halo' of respectability due to the assumption that government entities are acting in the public's best interest-and those that they partner with do the same. 262 255 We could also see this phenomenon painfully playing out in the initial glacial distribution of the COVID-19 vaccine across the country. States had been distributing their allocation of the vaccine from the Strategic National Stockpile to both public health entities as well as hospitals, AMCs, and other types of private entities. 263 Although this may have made sense given the existing lack of infrastructure and funding of public health agencies, 264 backlash regarding the choices of some of those entities-and in particular AMCs which adopted rather luxurious de nitions of who counted as an 'essential employee'-was swi . 265 But this is a classic example of the problem with entrusting private entities with public goods-they are neither enabled (nor potentially particularly inclined) to act equitably at a public community level. As Wendy Parmet recently argued in her Atlantic essay on the privatization of public health:

Unquestionably, the private sector has a role to play in public health-just look at the private companies that produced the vaccines and the private hospitals that have cared for the ill. But to rely on it to protect the public's health is pure folly . . . . To depend now on the private sector to increase vaccination rates would further underscore America's tepid commitment to the basic principles of public health. 266 Thus, AMC/industry partnerships might not be the right framing to control data and biobank repositories. However, this should not prevent academia from setting standards for industry interactions. In fact, academia has done so successfully in the past. For example, in the wake of research establishing that even small gi s from pharmaceutical sales representatives in uenced physician prescribing practices, many AMCs set policies limiting or prohibiting sales representatives from campus. 267 These prohibitions, in turn, signi cantly altered prescribing practices (from predominantly drugs that had been heavily marketed to cheaper ones that were not) at the majority of implementing institutions. 268 Setting standards at the AMC level is one distinct possibility for controlling these relationships. 269 As an example, at the University of Michigan Medical School, we have set up a multidisciplinary Human Data and Biospecimen Release Committee which reviews all industry and researcher requests to commercialize participant health data and biospecimens collected at Michigan Medicine. 270 This Committee sets higher standards than those included in the human subjects research regulations, which we also voluntarily extend to all human subjects research at our institution. We require participant consent (with exceptions for rare diseases and some pediatric research) for all commercialization, and do not grandfather in data and biospecimens collected before the regulations required us to disclose this information. In addition, given the increasing risk of reidenti cation discussed above, we require commercialization consent of even data and biospecimens that will be provided to industry in deidenti ed form. 271 Another example of a potential AMC approach is controlling the data usage agreements necessary to transition industry data to academic researchers at most AMCs. 272 AMCs could require additional clarity regarding industry data provenance speci cally to ensure that the type of informed consent provided by participants meets the AMC's own expectations; avoiding the opportunity for AMC researchers to otherwise whitewash data that they could not have legally acquired themselves. Indeed, there has been minimal oversight or even acknowledgement of the consent pedigree of privately procured specimens and data in the published literature. And, although there has been some response to the moral turpitude of analyzing specimens and data taken from participants forcefully-such as via the Guatemala STD experiments, 273 Nazi medical experiments, 274 or Chinese prisoners 275 -there has been virtually no emphasis in nonegregious circumstances. For example, in a recent review of academic publications with data procured from private databanks, the type of original contributor consent was either not disclosed or was unclear almost half the time. 276 AMCs could begin to improve this system at the data use agreement level.

Another possibility is that AMCs could require IRB authorization of the primary research which generated the data in the rst place. While, as discussed above, IRB authorization might not be an actual legal requirement of all industry research, by refusing to publish secondary research with data acquired otherwise, AMCs could begin to shi behavior. Such an approach has been employed by journal editors in the past. For example, when 23andMe submitted one of its rst genome-wide association studies to PLoS Genetics in 2010, 277 editors noticed three major de cits: the protocol had not been prospectively reviewed by an IRB, there was concern over the type of consent obtained, and access to the underlying data was limited. PLoS Genetics editors published a concurrent comment explaining why they decided to publish the piece, despite these perceived shortcomings, given the work's (i) novel contribution to the literature and (ii) their independent assessment that the participants involved were neither coerced nor deceived. 278 Ultimately, editors argued that publication 'accompanied by an editorial providing transparent documentation of the process of consideration' was appropriate, in addition to their 'call for community input to spur e orts to standardize the IRB consent process' for that type of research. 279 The day the editorial was published, 23andMe sent out a press release emphasizing that IRB review was not legally required for its research-but that it would obtain review going forward 'to ensure that our work is in line with scienti c research best practices' . 280 In this case, the ability to publish knowledge gained from analysis of its databank made the databank a more valuable business asset itself-one for which 23andMe was willing to give up something of value (ie not having IRB oversight) in return. 281

In addition to better controlling the ow of data and specimens between AMCs and industry, AMCs can begin to improve informed consent practices at their own institution. As argued above, one of the reasons that the information contained in a consent form is so highly regulated is that it is easier than empirically validated methods of gaining informed consent (ie a conversation) to regulate in the rst place. The assumption is that if information about risks or burdens were disclosed in the form, they have been understood and accepted. We know this is not true. 282 But, given the new types of risks to individuals and bene ts to communities of secondary research, should we bother trying to continue to improve the individual informed consent process given the enormous time and burden that would entail? If the individual risks of secondary research are less, and we know that informed consent is generally ine ective anyway, is there a better solution?

Although a signature on the informed consent form will certainly remain legally required, AMCs can also attempt to better conscribe what they are asking of patients and participants contributing to secondary research banks in the rst place. By ensuring a baseline standard taking into account the risks and bene ts of secondary research, with buy in from representative community members, this 'rising tide can li all boats' and potentially better protect many more participants-even if some might not read or understand the forms.

One way to do this is by establishing some type of data review committee which will agree to prospective standards for what can be asked of participants in the rst place, rather than a retrospective check of informed consent (like the University of Michigan model). Not only would such a committee potentially resolve the imbalance of putting too much emphasis on individual consent and autonomy for low risk research, but it would also avoid the secondary issue that even when researchers attempt to get individual level consent, participants rarely comprehend what they are agreeing to.

At the committee level, patient representatives could engage in a more helpful conversation about risks, bene ts, and alternatives to research. In particular, given that we know that Black and Latino participants are more likely to be hesitant to share data and specimens, 283 we must ensure that these standards are not set at the 'average patient' standard-because that 'average' for many AMCs is likely to be of a prominently white cohort and therefore represent a white viewpoint. Informed consent standards should be responsive to a diversity of racial and ethnic viewpoints so as not to further discourage the diversity of racial and ethnic representation within research datasets.

Of course, dissenting individual participants would still be potentially subjugated via representation at the cohort level. But, given the justice and public bene cence opportunity for communities from enabling such research, and the low risk to individuals, this seems like a better compromise than the one we are making now (ie that many participants do not understand the forms and yet we move forward). We should instead be moving toward setting and enforcing higher standards across the board such that the individual informed consent conversation can focus on other preference-sensitive choices (eg amount of time participants are willing to commit to research in return for what value).

Therefore, although a more classic academic/industry partnership model might not be appropriate, there are several concrete steps AMCs can take to better control and set standards for their own data and specimen commercialization and academic researcher access to industry data and specimens, as well as resolve some of the lapses in protection of patients and participants at the federal level.

The future of scienti c advances via secondary research with biospecimens and health data is bright. However, the current strict governance of federally funded researchers (and, by association, most AMC researchers) and a decided lack of governance of privately collected data and specimens has created a stark imbalance. This inequity is increasingly leading to AMCs commercializing their own health data and specimens, in addition to securing additional data access from private holdings. But, though AMCs may have little control over new federal legislation or revising extant regulations, they do have control over supply and demand as well as the behavior of their researcher employees. Simply succumbing to inevitable privatization of data and biospecimen banking is not an acceptable solution for such an important public good. Instead, AMCs should move toward better controlling the proverbial revolving door between themselves and industry to continue to advance life-saving research while also protecting the interests of those whose data are supporting such advances.

Shadow Health Records, supra note 94

Encouraging Participation, supra note 8

Patient Preferences for Use of Archived Biospecimens omOncology Trials When Adequacy of Informed Consent Is Unclear

A Review of the Key Issues Associated With the Commercialization of Biobanks, 1

Encouraging Participation, supra note 8

Negotiating Commercial Interests in Biospecimens

Immortal Life of the Common Rule: Ethics, Consent, and the Future of Cancer Research, 35 J. C

Strategic Plan for Data Science

Time for NIH to Lead on Data Sharing

All of Us Research Program Investigators, The 'All of Us' Research Program

National Research Program Returns First Results to Local Participants

Among persons from whom biospecimens are obtained, the target percentage of persons in racial and ethnic minorities is more than 45% and that of persons in underrepresented populations is more than 75%

). cy-richard-branson-genetics

Reconceptualizing Consent for Direct-to-Consumer Health Services, 41 A

We argue that consent is most valid when we are asked to choose in equently, when the potential harms that result from the consent are easy to imagine, and when we have the correct incentives to consent consciously and seriously. The further we fall from this gold standard, the more a particular consent is pathological and thus suspect

Members of the general public expressed little concern about sharing health data with the companies that sold the devices or apps they used

Americans and Privacy: Concerned, Confused and Feeling Lack of Control Over Their Personal Information

Does Anyone Read the Fine Print? Consumer Attention to Standard Form Contracts, 43

While users were generally aware that consenting to a company's terms of use constitutes a legal contract, very few reported actually reading those agreements before consenting to them

GSK and 23andMe today unveiled an exclusive four-year collaboration that will focus on research and development of innovative new medicines and potential cures, using human genetics as the basis for discovery

But some customers were still surprised and angry, unaware of what they had already signed (and spat) away

Shadow health records, supra note 94

FaceApp: Is the Russian Face-Aging App a Danger to your Privacy?, F

Do not share your COVID-19 vaccine card on social media

we hold a scienti c review to evaluate proposals for the limited number of collaborative projects we can initiate. Applicants are informed of our committee decision approximately three months a er the deadline

Head-to-Head Randomized Trials are Mostly Industry Sponsored and Almost Always Favor the Industry Sponsor, 68

The drug shortage crisis in the United States: Causes, Impact, and Management Strategies

The Challenge of Reforming Nutritional Epidemiologic Research

Psychological Science in the news again: CNN retracts story on hormone-voting

Policy for Data Management, supra note 2

Because all the authors were not granted access to the raw data and the raw data could not be made available to a third-party auditor, we are unable to validate the primary data sources underlying our article

RETRACTED: Hydroxychloroquine or Chloroquine With or Without a Macrolide for Treatment of COVID-19: A Multinational Registry Analysis

But for research involving the use of unique biological materials, such as bacterial strains and other types of self-replicating cells, publication in writing alone may not be su cient to satisfy this replicability norm. To replicate the authors' results, subsequent investigators may need access to identical materials. By sharing access to unique materials, however, the publishing scientist not only enables other scientists to replicate her claims

A resource is prone to overuse in a tragedy of the commons when too many owners each have a privilege to use a given resource and no one has a right to exclude another. By contrast, a resource is prone to underuse in a "tragedy of the anticommons" when multiple owners each have a right

Proprietary Rights, supra note 220, at 198 ('Withholding materials is a relatively inconspicuous departure from scienti c norms. It occurs a er publication and is not apparent from the written text

publishing scientists with exclusive access to such materials have an opportunity to gain recognition while retaining a future advantage over their research competitors. This con ict between norms and incentives is aggravated when the materials (or the discoveries they facilitate) have potential commercial value

Collaborative e orts built on trust can convert zero-sum relationships into positive-sum relationships, where data sharing serves everyone's interests 246

very di erent where the standard's bene ts are externalities, ie ow indiscriminately to every member of the community. The most important example is where backlash damages rms that had nothing to do with the scandal

The Best Practices provide a policy framework for the collection, retention, sharing, and use of Genetic Data generated by consumer genetic and personal genomic testing services

The Best Practices provide a policy framework for the collection, retention, sharing, and use of Genetic Data generated by consumer genetic and personal genomic testing services

) ('Indeed, the private sector is o en seen as nimbler than the government precisely because it can eschew the necessity of public input and the threat of public accountability

Northeastern University starts vaccinating its ont-line sta

States will need billions to distribute the Covid vaccine as federal funding falls short

At Elite Medical Centers, Even Workers Who Do not Qualify Are Vaccinated

Employers' Vaccine Mandates Are Representative of America's Failed Approach to Public Health, A

Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing

Sharing Health Data and Biospecimens with Industry: A Principle-Driven, Practical Approach

Waiting for Data: Barriers to Executing Data Use Agreements

From in vivo to in vitro: How the Guatemala STD Experiments Transformed Bodies into Biospecimens, 96 M Q

The Echo of Nuremberg: Nazi Data and Ethics

Journals retract more than a dozen studies om China that may have used executed prisoners' organs

Genetic data partnerships, supra note 134

WebBased, Participant Driven Studies Yield Novel Genetic Associations for Common Traits

Consent and Internet-Enabled Human Genomics

The Google of Healthcare': Enabling the Privatization of Genetic Bio/Databanking

All so-called codes are based on the bland assumption that meaningful or informed consent is readily available for the asking . . . this is very o en not the case. Consent in any fully informed sense may not be obtainable. Nevertheless, except, possibly, in the most trivial situations, it remains a goal toward which one must strive for sociologic, ethical and clear-cut legal reasons. There is no choice in the matter

Governing secondary research use of health data and specimens • 31 such as patents. In this context, high transaction costs make use less likely, aggravating the risk of an anticommons. 225 Last, companies might decrease or limit researcher access because of a new business focus, leadership, or regulation. For example, when law enforcement used the GEDmatch database surreptitiously to solve the 'Golden State Killer' case, there was substantial backlash. 226 GEDmatch only listlessly pursued claims against the law enforcement o cials who violated their terms and conditions by making up an identity. 227 The company was then bought by Verogen, a forensic genomics rm, whose speci c intent was to aid in law enforcement searches. The database, including the genomic data of over 1.3 million users, was sold en masse without so much as an a rmative notice to contributors. GEDmatch then updated its Terms of Service to disclose the acquisition, and users were locked out of accessing the platform until they agreed to the new terms. 228 Relatedly, in February 2021, 23andMe announced its decision to go public-a move for which the implications are not yet clear. 229

We know that what contributors care about is use of their health data and specimens. 230 We know that they are particularly suspect when health data and specimens exchange hands across types of entities. 231 scholars have theoretically supported an opt-out or no consent system for public health purposes, 233 although-when asked-few potential contributors agree. 234 But, because many previous proposals either required private industry to self-restrict when competitors might not, or were founded on the government issuing uid and comprehensive regulatory revisions when it apparently cannot, none have yet fully stemmed the tide of privatization. This section rst explores industry self-governance as one alternative to the current regulatory structure. Given its limitations, it will then discuss alternative approaches AMCs can take to control the commercialization of held health data and biospecimens as well as academic researcher use of industry data, in addition to improving standards for informed consent for both patients and participants. V.A. Self-Governance as an Alternative?Stephen Maurer, in his book on Self-Governance in Science, argues that selfgovernance of industry can be a viable alternative when regulatory mechanisms have proven ine ective. 235 There are many types of industries where self-governance can be attractive, both to ward o potentially more restrictive government regulation, or because the consumer base insists on a standard for behavior without assurance of which they will no longer purchase the product. 236 In addition, private industry players are in a position to possess the most relevant information regarding e ective strategies for controlling industry behavior. 237 They may also be able to reach a larger swath of players than government agencies, which are constrained by congressional scope and funding. 238 In particular, industries where players are limited and derivations from market expectations may be attributed across all entities might be particularly motivated to self-regulate. 239 ('There was little enthusiasm for MICs to operate under a public health model where individual participation is mandatory or there is an opt-out consent option rather than opt-in. Interviewees commented that an opt-out model would require a high level of trust that is unlikely to be found in the U.S. population given past incidents of research misconduct (and concerns about discrimination in healthcare and other domains), especially among minority/underrepresented populations.'). 235 S M. M , S -G S , at 180 (2017) ('conventional government has tried and failed, sometimes repeatedly, to address particular policy problems.'). 236 Id., at 239 ('Nearly all scholars agree that rms are more likely to organize self-governance when downstream markets are "highly branded" so that demand depends less on objective attributes than "marketing" so that demand depends less on objective attributes than "marketing" and a "constructed brand identity" which makes them vulnerable to "shi s in consumer preferences."'). 237 Id., at 179 ('US o cials have long recognized that private organizations o en possess more information and can produce better standards.'). 238 Id., at 179, 181.